Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan With or Without Tislelizumab in Advanced Thyroid Cancer
NCT07068542Phase 2Recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in anaplastic thyroid carcinoma (ATC), poorly differentiated thyroid carcinoma (PDTC), differentiated thyroid cancer (DTC), sponsored by Zhejiang Provincial People's Hospital. Started Jul 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
anaplastic thyroid carcinoma (ATC)poorly differentiated thyroid carcinoma (PDTC)differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT07068542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07068542.